TEM is integrating externally developed AI pathology into its ecosystem to improve risk prediction and personalize prostate ...

Prostate-specific antigen (PSA) blood testing likely reduces the risk of death from prostate cancer, found a new review ...

The 25-year follow-up of the GÖTEBORG-1 trial 5 assessing active surveillance for screen-detected low and intermediate risk ...

People with localized prostate cancer treated according to guidelines developed by an international panel of doctors are more likely to die of something other than the disease, new research shows. A ...

A polygenic risk score was able to detect a high proportion of clinically significant prostate cancer. Cancer would not have been detected in 71.8% of patients with the use of PSA or MRI screening.

Long-term follow-up consistent with earlier report, a hint of benefit in high-grade diseas ...

Less is more in the case of this cancer treatment. The most common form of cancer among men in the US, after skin cancer, ...

Screening for prostate cancer using a blood test likely reduces the risk of dying from prostate cancer and may also reduce the risk of dying from any cause. Screening likely makes little to no ...

A new urine test performed better than PSA-based testing and MRI for monitoring low-risk prostate cancers on active ...

The best way to fight cancer is to detect and start treatment early. Dr Atangwho shares signs to watch out for prostate ...

For patients with intermediate or lower high-risk prostate cancer, side effects are similar with two- or five-fraction ...

A breakthrough study has identified the genetic risk factors that contribute to increased prostate cancer in African men. The study, the largest of its kind, recruited 7,500 men from eastern, southern ...